Medicare Part D Coverage Gap Discount Proposal Challenged In Study
Executive Summary
Analysis sponsored by a biopharma-backed group challenges MedPAC proposal for changing Part D procedures in a way that could reduce beneficiary incentives to choose high-cost branded drugs while in the coverage gap.
You may also be interested in...
Part D Reform Proposals From MedPAC May Find Traction After Election
Advisory group’s cost control recommendations on reinsurance, partial fills, and preferred specialty tiers could end up on the legislative agenda, particularly if Hillary Clinton is president.
Medicare’s Final Coverage Decision On Alzheimer’s Drugs: Thoughts From A Former CMS Chief
Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.
Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told
Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.